The candidate vaccine antigen rsPilA targets the major subunit of NTHI Tfp and is highly effective as an immunogen for both the prevention and the therapeutic resolution of NTHI-induced otitis media in experimental models (11, 12). This evidence concerns the gene TRIM39 and otitis media.